GSK Patient Assistance Program for Prescription Medicines
This program can help you receive certain GSK prescription medicines at no cost.
You might be eligible for this program if:
- You are uninsured
- You have Medicare and meet other program requirements
- Live in the United States or Puerto Rico (or the US Virgin Islands for certain medicines)
- Meet financial income eligibility criteria
Patients enrolled in an Alternate Funding Program are not eligible for GSK PAP enrollment.
What is an Alternate Funding Program?
Certain health insurance providers, often through a third-party vendor, implement Alternate Funding Programs, that attempt to utilize charitable patient assistance programs to divert resources intended for uninsured patients instead of providing coverage for certain medicines. These insurance providers deny insurance coverage for selected medications and, instead, require that the patient apply to charitable patient assistance programs despite being enrolled in a health insurance plan. When the patient is approved for the patient assistance program, the expense of the medication shifts from the health insurance provider to the charitable organization. Both the health insurance provider and the third-party vendor profit from these programs, also referred to as Specialty Carve-Outs.
Medicare Information
As a reminder, Medicare eligibility for the GSK Patient Assistance Program (PAP) is based on a calendar year like Medicare. In order to receive support for this calendar year, we must receive your complete enrollment form and supporting documentation as outlined on the enrollment form by 12/27 to be assessed for eligibility this year.
To qualify for GSK PAP in 2024, you will need to meet all eligibility requirements, including having met the out of pocket spend, if applicable, for your program on or after January 1, 2024.
Recently Discontinued Products
ADVAIR DISKUS, ADVAIR HFA, BECONASE AQ, FLOVENT HFA, FLOVENT DISKUS AND IMITREX NASAL SPRAY will be fully removed from GSK PAP for ALL PATIENTS effective 12/31/2023.
